 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
5 News |  |
- | low-dose hrIL-2 / Beijing SL Pharma
New P2 trial, Combination therapy: Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy (clinicaltrials.gov) - Jan 22, 2020
P2, N=20, Not yet recruiting, Sponsor: Peking University People's Hospital
- | low-dose hrIL-2 / Beijing SL Pharma
Trial completion, Trial completion date, Trial primary completion date: A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sj (clinicaltrials.gov) - Mar 15, 2018
P2, N=60, Completed, Sponsor: Peking University People's Hospital
Recruiting --> Completed | Trial completion date: Dec 2016 --> Aug 2017 | Trial primary completion date: Jun 2016 --> Mar 2017
- low-dose hrIL-2 / Beijing SL Pharma
Enrollment open: Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis (clinicaltrials.gov) - Nov 14, 2015
P2, N=60, Recruiting, Sponsor: Peking University People's Hospital
Recruiting --> Completed | Trial completion date: Dec 2016 --> Aug 2017 | Trial primary completion date: Jun 2016 --> Mar 2017 Not yet recruiting --> Recruiting
- | low-dose hrIL-2 / Beijing SL Pharma
New P2 trial: Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis (clinicaltrials.gov) - Jun 10, 2015
P2, N=60, Not yet recruiting, Sponsor: Peking University People's Hospital
- | low-dose hrIL-2 / Beijing SL Pharma
New P2 trial: A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov) - Jun 8, 2015
P2, N=60, Recruiting, Sponsor: Peking University People's Hospital
- | low-dose hrIL-2 / Beijing SL Pharma
New P2 trial: A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sj (clinicaltrials.gov) - Jun 6, 2015
P2, N=60, Recruiting, Sponsor: Peking University People's Hospital